Amphotericin b lipid complex Side Effects
Medically reviewed by Drugs.com. Last updated on Aug 9, 2023.
Applies to amphotericin b lipid complex: suspension.
Serious side effects
Along with its needed effects, amphotericin b lipid complex may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking amphotericin b lipid complex:
- Chills and fever
- nausea and vomiting
- Difficulty in breathing
- sore throat and fever
- unusual bleeding or bruising
- unusual tiredness and weakness
- Increased or decreased urination
Other side effects
Some side effects of amphotericin b lipid complex may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- loss of appetite
- stomach pain
For Healthcare Professionals
Applies to amphotericin b lipid complex: intravenous suspension.
The most common clinical side effects in clinical trials were chills, increased creatinine, pyrexia, hypokalemia, nausea, and vomiting.[Ref]
Very common (10% or more): Chills (up to 18%), fever/pyrexia (up to 14%), multiple organ failure (11%)
Common (1% to 10%): Sepsis, infection, pain, chest pain, increased alkaline phosphatase
Frequency not reported: Malaise, weight loss, increased lactate dehydrogenase, shivering, generalized edema, asthenia, peripheral edema
Very common (10% or more): Increased serum creatinine (up to 13%)
Common (1% to 10%): Renal failure, renal impairment, increased BUN/urea
Frequency not reported: Decreased renal function, abnormal kidney function
Common (1% to 10%): Hypokalemia, electrolyte imbalance (including increased blood potassium, decreased blood magnesium)
Frequency not reported: Anorexia, hypomagnesemia, hyperkalemia, hypocalcemia, hypercalcemia, acidosis, hyperamylasemia, hypoglycemia, hyperglycemia, hyperuricemia, hypophosphatemia, hypernatremia, hyponatremia, hyperchloremia
Postmarketing reports: Hyperammonemia[Ref]
Common (1% to 10%): Nausea, vomiting, diarrhea, gastrointestinal hemorrhage, abdominal pain, nausea and vomiting
Frequency not reported: Melena, dyspepsia, epigastric pain, cramping, constipation
Postmarketing reports: Peritonitis[Ref]
Common (1% to 10%): Thrombocytopenia, leukopenia, anemia
Frequency not reported: Coagulation defects, blood dyscrasias (including eosinophilia), leukocytosis, decreased thromboplastin
Postmarketing reports: Pancytopenia[Ref]
Common (1% to 10%): Headache, tremor
Uncommon (0.1% to 1%): Convulsions, neuropathy
Frequency not reported: Peripheral neuropathy, deafness, hearing loss, tinnitus, transient vertigo, cerebral vascular accident, extrapyramidal syndrome, other neurologic symptoms, somnolence
Uncommon (0.1% to 1%): Anaphylactic response
Frequency not reported: Anaphylaxis, allergic reactions (including bronchospasm, wheezing, asthma), anaphylactoid reactions, infusion hypersensitivity reactions (including abdominal pain, nausea, vomiting, myalgia, pruritus, maculopapular rash, fever, hypotension, shock, bronchospasm, respiratory failure)[Ref]
Common (1% to 10%): Hypotension, cardiac arrest, hypertension, tachycardia, cardiac arrhythmias
Uncommon (0.1% to 1%): Shock
Frequency not reported: Cardiac failure, myocardial infarction, thrombophlebitis, cardiomyopathy, arrhythmias, ventricular fibrillation, atrial fibrillation, phlebitis, supraventricular tachycardia, abnormal ECG, cyanosis
Postmarketing reports: Asystole, bradycardia, hemorrhage, vasodilation[Ref]
Common (1% to 10%): Respiratory failure, dyspnea, pneumonia, respiratory disorder, asthma
Postmarketing reports: Bronchospasm[Ref]
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus
Frequency not reported: Maculopapular rash, erythema multiforme, skin ulcer, exanthema
Postmarketing reports: Exfoliative dermatitis[Ref]
Uncommon (0.1% to 1%): Injection site reaction
Frequency not reported: Injection site inflammation, injection site hypersensitivity[Ref]
Uncommon (0.1% to 1%): Myalgia
Frequency not reported: Myasthenia, bone pain, joint pain, muscle pain[Ref]
Common (1% to 10%): Hyperbilirubinemia, abnormal liver function tests
Frequency not reported: Oliguria, anuria, impotence, dysuria, hematuria, urinary tract infection, pyuria, urinary tract disorder
Postmarketing reports: Hyposthenuria, incontinence[Ref]
Frequency not reported: Visual impairment, diplopia
Frequency not reported: Confusion, insomnia, anxiety
Postmarketing reports: Agitation
More about amphotericin b lipid complex
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: polyenes
- En español
Related treatment guides
1. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN. Limited toxicity of prolonged therapy with high doses of amphotericin b lipid complex. Clin Infect Dis. 1995;21:1154-8.
2. Oravcova E, Mistrik M, Sakalova A, Drgona L, Kollar T, Helpianska L, Ilavska I, Sorkovska D, Spanik S, Kukuckova E, Krcmery V. Amphotericin b lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy. 1995;41:473-6.
3. Product Information. Abelcet (amphotericin B lipid complex). Liposome Company Inc, The.
4. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fanhavard P, Eng RHK, Patterson TF,. Amphotericin b lipid complex compared with amphotericin b in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:315-21.
5. Sundar S, Murray HW. Cure of antimony-unresponsive indian visceral leishmaniasis with amphotericin b lipid complex. J Infect Dis. 1996;173:762-5.
6. Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother. 1997;31:1174-86.
7. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53:540-3.
8. Cerner Multum, Inc. UK Summary of Product Characteristics.
9. Cerner Multum, Inc. Australian Product Information.
10. Sorkin P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P. Administration of amphotericin b in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med. 1996;24:1311-5.
11. Gales MA, Gales BJ. Acute renal failure with amphotericin B in lipid emulsion. Ann Pharmacother. 1996;30:1036.
12. Rowles DM, Fraser SL. Amphotericin B lipid complex (ABLC)-associated hypertension: Case report and review. Clin Infect Dis. 1999;29:1564-5.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.